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ABSTRACT 
Neurodegeneration is thought to be the major cause of ongoing, irreversible disability in the 
progressive stages of Multiple Sclerosis (MS). Gamma-aminobutyric acid (GABA) is the 
principle inhibitory neurotransmitter in the brain, and is needed for normal brain function. 
The aims of this study were to investigate if GABA levels (i) are abnormal in secondary 
progressive (SP) MS patients when compared with healthy controls; and (ii) correlate with 
physical and cognitive performance in this patient population.  
 
Thirty patients with SPMS and 17 healthy controls underwent single-voxel MEGA-PRESS 
MRS at 3T, to quantify GABA levels in the prefrontal cortex, right hippocampus and left 
sensorimotor cortex. All subjects were assessed clinically and underwent a cognitive 
assessment. Multiple linear regression models were used to compare differences in GABA 
concentrations between patients and controls adjusting for age, gender, and tissue fractions 
within each spectroscopic voxel. Regression was used to examine the relationships between 
the cognitive function and physical disability scores specific for these regions with GABA 
levels, adjusting for age, gender, and total N-acetyl-aspartate and Glutamine-Glutamate 
complex levels.  
 
When compared with controls, patients performed significantly worse on all motor and 
sensory tests, and were cognitively impaired in processing speed and verbal memory. Patients 
had significantly lower GABA levels in the hippocampus (adjusted difference = -0.403mM, 
95% confidence intervals (CIs) -0.792, -0.014, p=0.043) and sensorimotor cortex (adjusted 
difference = -0.385mM, 95% CIs -0.667, -0.104, p=0.009) compared with controls. In 
patients, reduced motor function in the right upper and lower limb was associated with lower 
GABA concentration in the sensorimotor cortex. Specifically for each unit decrease in 
GABA levels (in mM), there was a predicted -10.86 (95% CIs -16.786, -4.482) decrease in 
grip strength (kg force) (p<0.001) and -8.74 (95% CIs -13.943, -3.015) decrease in muscle 
strength (p<0.006).  
This study suggests that reduced GABA levels reflect pathological abnormalities that may 
play a role in determining physical disability. These abnormalities may include decreases in 
the pre- and post-synaptic components of the GABAergic neurotransmission and in the 
density of inhibitory neurons. Additionally, the reduced GABA concentration may contribute 
to the neurodegenerative process, since it may result in increased firing of axons, with 
consequent increased energy demands, which may lead to neuroaxonal degeneration and loss 
of the compensatory mechanisms that maintain motor function. This study supports the idea 
that modulation of GABA neurotransmission may be an important target for neuroprotection 
in MS.  
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INTRODUCTION 
There is a need to understand the mechanisms of neurodegeneration in progressive MS (Fox 
et al., 2012). Secondary Progressive (SPMS) develops after an initial RRMS course (typically 
10-15 years), with or without acute exacerbations during the progressive course (Lublin et al., 
2014). This results in irreversible and continuous neurological decline. There is a decrease in 
the development of new inflammatory lesions, but disability accumulation continues, which 
is likely to be due to ongoing neuroaxonal loss, the mechanisms for which include 
degeneration of chronically demyelinated white matter axons (Trapp et al., 1999) and 
progressive cortical demyelination (Kutzelnigg et al., 2005). SPMS results in significant 
motor and cognitive impairment in affected patients. Cognitive dysfunction is common, with 
prevalence rates of between 43% and 70% (Langdon et al., 2012) and affects information 
processing speed (Amato et al., 2010), episodic memory and executive function (Strober et 
al., 2009). The pathological processes underlying clinical disability in MS are complex, and 
include neuronal and glial changes, with associated structural and metabolic abnormalities; 
these abnormalities may be detected in vivo by metabolic and molecular imaging (Ciccarelli 
et al., 2014). A recent study found that in MS patients, reduced concentrations of grey matter 
Glutamate, the main excitatory neurotransmitter of the human brain, correlated with worse 
memory function (Muhlert et al., 2013), suggesting that abnormalities in the neurotransmitter 
pathways may play a role in neurodegeneration, which underpins disability in MS. 
Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the brain 
(DeFelipe, 1993) and is produced from glutamate by L-glutamic acid decarboxylase (GAD) 
within GABAergic neurons (Chang et al., 2003). GABA is then metabolised to succinic acid 
semialdehyde by GABA transaminase (GABA-T) and then to succinate, mainly within 
astrocytic mitochondria (Chang et al., 2003). GABA is needed for normal brain function, 
synaptic plasticity, cortical adaptation and reorganisation (Stagg, 2014). Altered GABA 
concentrations have been detected in a number of conditions, including increases and 
reductions observed in epilepsy (MacDonald et al., 2011), and reductions in anxiety disorders 
(Durant et al., 2010), schizophrenia (Reynolds et al., 2002) and autism (Gaetz et al., 2014).  
A number of studies in idiopathic generalised epilepsy found an increase in GABA levels in 
the occipital (Simister et al., 2003) and frontal lobes (Chowdhury et al., 2014) of patients 
when compared with controls. It has been reported that GABAergic inhibition is one of the 
mechanisms involved in use-dependent plasticity in the intact human motor cortex (Stagg et 
al., 2011; Levy et al., 2002; Floyer-Lea et al., 2006; Butefisch et al., 2000). Changes in 
GABA concentration in the sensorimotor cortex during motor learning have been 
demonstrated (Floyer-Lea et al., 2006). One pilot study carried out in RRMS (Bhattacharyya 
et al., 2013) found that reduced motor performance correlated with increased GABA levels in 
the sensorimotor cortex. The increased GABA concentration was also associated with 
increased motor activation on functional MRI. Despite limitations, these in vivo results 
suggest that cortical reorganisation or adaptation occurring in the sensorimotor cortex in 
patients with RRMS, as reflected by increased fMRI response, is linked with increased 
GABA levels, and is a possible compensatory mechanism that maintains motor function 
(Bhattacharyya et al., 2013).  
In vivo quantification of GABA using 1H-MRS spectroscopy is challenging due to the 
spectral overlap of GABA with more abundant metabolites, such as N-acetyl-asparate (NAA) 
at 2 ppm, Creatine (Cr) at 3 ppm and glutamate (Glu) and glutamine (Gln) at 2.3 ppm (Puts 
and Edden, 2012). Spectral editing methods such as MEGA-PRESS (MEscher GArwood - 
Point RESolved Spectroscopy), have allowed the discrimination of GABA from these 
metabolites (Mescher et al., 1998). The MEGA-PRESS sequence also allows quantification 
of total N-acetyl-aspartate (tNAA) and the Glutamine-Glutamate complex (Glx). tNAA is a 
well-established spectroscopic marker of neuronal loss and/or metabolic dysfunction (Moffett 
et al., 2007) that is often reduced in central nervous system diseases including multiple 
sclerosis (MS) (Kirov et al., 2013; Achnichts et al., 2013). We have reported lower levels of 
Glx in the spinal cord of primary progressive MS patients compared to healthy controls, and 
have suggested that these reflect dysfunction in the glutamatergic pathway and neuroaxonal 
loss (Abdel-Aziz et al., 2015). 
Thus, the finding of: (i) reduced concentrations of Glutamate, which is the precursor of 
GABA, as observed in post-mortem (Wegner et al., 2006) and in vivo MRS studies in 
progressive MS (Sastre-Garriga et al., 2005); (ii) reduced GABA-related gene transcripts and 
density of inhibitory neuronal processes in the motor cortex of autopsied MS brains (Dutta et 
al., 2006); and (iii) impaired compensatory mechanisms occurring in SPMS compared with 
RRMS (Rocca et al., 2005), lead us to hypothesise that GABA levels are reduced in SPMS 
patients when compared with  healthy controls and that they correlate with increased clinical 
disability. In order to test these two hypotheses, we measured the concentrations of GABA in 
the prefrontal cortex, right hippocampus (involved in visual and verbal memory) and left 
sensorimotor cortex using MEGA-PRESS MRS. We investigated whether there was an 
association between memory function and GABA concentration in the grey matter regions of 
the prefrontal cortex and hippocampus, and between sensory and motor function and GABA 
concentration in the left sensorimotor cortex. We examined if these associations were 
independent of imaging measures of structural damage, such as those sensitive to axonal loss 
and demyelination, derived from the same areas, and of tNAA and Glx, obtained within the 
same spectroscopic voxels. 
 
 
  
MATERIALS & METHODS 
 
Subjects 
Patients with a diagnosis of secondary progressive MS (SPMS) who were not taking any 
medication that affects the GABAergic systems (e.g. Baclofen), for a minimum of 6 months 
prior to the time of scanning, and with an Expanded Disability Status Scale (EDSS) of 
between 4.0 - 6.5, were recruited into the study. Healthy controls were also recruited. Written 
informed consent was obtained for participants in the study, which was approved by our local 
research ethics committee.  
 
Cognitive Tests 
Patients and controls were assessed using a range of cognitive tests. Speed of information 
processing was assessed using the Symbol-Digit Modalities Test (SDMT) (Lezak et al., 
2004), and the 3-second Paced Auditory Serial Addition Test (PASAT) (Rao et al., 1990), for 
which z-scores were obtained with reference to published norms (Fischer et al., 1999). 
Executive function was measured using the Stroop colour-word interference test (Trenerry et 
al., 1989) and Hayling sentence completion test (Burgess and Shallice., 1996).  Verbal 
memory was assessed using The California Verbal Learning Test – II (CVLT-II) for 
immediate and delayed recall (Delis et al., 2000) and visuospatial memory was assessed 
using the Brief Visuospatial Memory Test Revised (BVMT-R) (Benedict et al., 1997). 
Working memory was assessed using the digit span from the Wechsler Adult Intelligence 
Scale-III (Wechsler et al., 1997). Premorbid IQ was measured using the National Adult 
Reading Test (Nelson, 1982). Levels of anxiety and depression were measured using with the 
Hospital Anxiety and Depression Scale (Zigmond et al., 1983).  
Failure of a test (SDMT, Stroop, PASAT, Hayling Sentence Completion, Digit Span, CVLT-
II and BVMT-R), was defined as a score of two or more SDs below the mean of the controls. 
Patients with significant cognitive impairment were defined as those showing failure on at 
least two tests.  
 
Clinical Assessments 
All patients were assessed using the Expanded Disability Status Scale (EDSS) (Kurtzke, 
1983). All patients and controls were also assessed using the 9-Hole Peg Test (9-HPT) 
(Goodkin et al., 1988), Timed 25-Foot Walk Test (TWT) (Cutter et al., 1999), and the 
Medical Research Council (MRC) scoring system for muscle strength of the right upper and 
lower limb (Medical Research Council, 1943; Dyck et al., 2005). Z-scores were calculated 
for the 9-HPT and TWT from normative values displayed in the National Multiple Sclerosis 
Society Task Force database (Fischer et al., 1999).  Mean grip strength from the right upper 
limb was measured using the Jamar hydraulic dynamometer (Sammons Preston. 
Incorporated, Bolingbrook, IL, USA) (Svens and Lee, 2005). The average of two trials for the 
TWT and the average of two trials for the 9-HPT were calculated (Fischer et al., 1999).  
Vibration perception thresholds (VPTs) were measured using the biosthesiometer (Bio-
Medical Instrument Company, Newbury, Ohio) from both the right lateral malleolus and the 
right ulnar styloid process. Mean VPTs were calculated and used in the analysis. The right 
upper and lower limb scores from the motor and sensory tests were only included in the 
analysis as GABA concentration was estimated in the left sensorimotor cortex.  
 
 
  
Magnetic Resonance Imaging Protocol 
All scans were performed using a 3T Achieva system (Philips Medical Systems, Best, 
Netherlands) with a 32-channel head coil.  
 
Single-Voxel Spectroscopy 
Sagittal T1-, coronal T2- and axial proton density-weighted scans were used for voxel 
placement in the three grey matter (GM) regions (prefrontal cortex, right hippocampus and 
left sensorimotor cortex). 
Due to the significant overlapping signals of GABA with other metabolites, non-invasive 
measures of GABA in the brain were acquired using the widely used MEGA-PRESS editing 
sequence (Mescher et al., 1998), with parameters TR= 2000ms, TE = 68ms, MOIST water 
suppression, pencil-beam automated shimming,  and editing pulses centred at 1.9 and 7.5ppm 
on each alternate scan. The dimensions and averages for the volume of interest (VOI) were as 
follows: (1) right hippocampus: dimensions 30 x 19.2 x 16 mm3, VOI volume = 9.22 mls, 
576 averages; (2) prefrontal cortex: dimensions 28 x 30 x 22 mm3, VOI volume = 18.48 mls, 
432 averages; and (3) left sensorimotor cortex: dimensions 35 x 34 x 22 mm3, VOI volume = 
26.18 mls, 400 averages. The acquisition and analysis protocol used in this study followed 
recently published guidelines for GABA-edited MRS at 3 T using MEGA-PRESS (Mullins et 
al., 2014). Example placements of each VOI can be seen in Figure 1. 
A non-water suppressed scan was also acquired with the same parameters (24 averages in one 
block), to provide an internal water reference to metabolite concentrations.  TARQUIN was 
used to estimate the concentrations of GABA, total N-acetyl-aspartate (tNAA), and Glx 
(Wilson et al., 2011). tNAA refers to the sum of NAA (N-acetylaspartate) + NAAG (N-
acetylaspartyl glutamate) and [Glx] refers to the sum of glutamate and glutamine.  
 
Spectral Quantification 
Spectral quality was assessed using Cramer-Rao-Lower-Bounds (CRLB) values provided by 
TARQUIN. Only data that had CRLB values of ≤20% were included in the analysis. From 
the participants, datasets for 6 controls and 14 patients had to be excluded from the 
hippocampus due to Cramer-Rao-Lower-Bounds (CRLB) values larger than 20% (Near, 
2014), and one patient’s dataset was excluded from the hippocampus due to time constraints. 
The hippocampus is technically very challenging due to its small size, the strong 
susceptibility to effects of nearby cranial air and bone, as well as the pulsatile cerebrospinal 
fluid (CSF) surrounding it (Solanky et al., 2013). In the prefrontal cortex, datasets from 3 
controls and 1 patient were excluded due to CRLB values greater than 20%. In the 
sensorimotor cortex, 2 controls and 1 patient were excluded due to CRLB values greater than 
20% and 4 patient datasets were not acquired due to time constraints.  
 
MR Imaging 
Participants underwent axial proton density / T2-weighted imaging which was acquired using 
a dual-echo turbo spin echo (TSE) sequence (TR = 3500 ms; TE = 19/85 ms; flip angle α = 
90o; FOV = 240 x 180 mm2; with spatial resolution of 1x1x3mm3), which was used to mark 
T2-hyperintense lesions. We outlined T2-hyperintense lesions in all SPMS participants on the 
axially acquired T2-weighted images using a semi-automated edge finding tool in JIM v. 6, 
then recorded the volume of T2-weighted lesions in millilitres for each subject. 
 
For calculation of brain tissue volumes a 3D T1-weighted magnetisation-prepared gradient-
echo sequence was used (TR = 6.9 ms; TE = 3.1 ms; TI = 824 ms; flip angle α = 8o; FOV = 
256 x 256 mm2; voxel size = 1 x 1 x 1 mm3). The GM, WM and cerebrospinal fluid (CSF) 
masks were obtained by segmentation of the volumetric T1-weighted scans, which were used 
to calculate the fractional tissue content of each spectral VOI.  
 
Hypointense lesions on the T1-weighted volume scan were marked and filled with values 
consistent with normal-appearing white matter signal intensity to prevent misclassification of 
tissue during segmentation (Chard et al., 2010).  Segmentation of the lesion-filled image was 
then performed using the ‘new_segment’ function in SPM8 (statistical parametric mapping; 
Wellcome Trust Centre for Neuroimaging, University College London (UCL) Institute of 
Neurology, London). The brain parenchymal fraction (the sum of white and grey matter 
relative to total intracranial volume) was then recorded for each subject.  
 
All subjects also underwent an axial 3D double inversion recovery (DIR) scan (with a spatial 
resolution of 1 x 1 x 3 mm3, TR = 16000 ms; TE = 9.9 ms; T1 = 3400/325 ms). Following 
recent consensus recommendations, DIR lesions were marked for each patient (Geurts et al., 
2011). In order to count the number of T2 and DIR lesions within each spectroscopic voxel, 
we created a binary mask of the spectroscopic voxel by using the absolute scan geometry of 
the PD/T2 and DIR volumes as a reference.  
 
  
Statistical analysis 
Differences in cognitive and clinical performance and metabolite concentrations between 
groups 
 
Differences between patients and controls were examined using independent-samples t-tests. 
For GABA measures, differences were examined for each region separately using multiple 
linear regression to adjust for age, gender, GM and WM fraction. Since the concentrations of 
tNAA and Glx can also be estimated within the same voxel using the same protocol, we 
completed the investigation by looking at these metabolites in the model.  
 
Associations between clinical disability and regional GABA levels in patients and controls 
Associations between GABA levels and clinical disability were examined in patients and 
controls combined using multiple regressions of the clinical variables on GABA predictors 
with interaction terms (i.e. group x GABA measure) to allow different associations between 
patients and controls to be estimated. These models allowed adjustment for covariates, such 
as age, gender, and premorbid IQ (when appropriate). Potential confounders, such as GM 
lesions within the spectroscopic VOI, anxiety and depression were also examined by 
including these as covariates. GM lesions within the spectroscopic VOI were not included in 
the final model, as they did not contribute to the model. In these models, variables describing 
executive function and information processing speed were regressed on prefrontal GABA 
concentration, those describing memory (visual and verbal) functions on hippocampus 
GABA concentration, and those describing right upper and lower limb motor and sensory 
ability on sensorimotor cortex GABA concentration. 
In patients only, to assess independence of GABA concentration from tNAA or Glx as 
predictors, tNAA or Glx was added to models with GABA in cases where GABA was 
significantly or borderline significantly associated with a clinical score.  
 Where regression residuals showed deviation from normality, we used bias-corrected 
nonparametric bootstrap with 1,000 replicates to obtain confidence intervals (CIs) and p-
values. Significance was set at 5% level. 
All analyses were performed in Stata 13.1 (Stata Corporation, College Station, Texas, USA). 
  
RESULTS 
Participant demographics and characteristics 
Thirty patients with SPMS (mean age = 51.3 yrs (SD9.6), 23 females, median EDSS=6 
(range 4 – 6.5)) and 17 healthy controls (mean age = 46.3 yrs (SD11.7), 9 females) were 
studied. Overall patients had a short duration of progressive disease (mean duration of 
progressive disease = 4 yrs) and a moderate level of disability. Further details on patient 
demographic characteristics and disability are summarised in Table 1.   
Clinical disability 
As expected, patients had significantly slower processing speed on the SDMT (p < 0.001) 
and had worse verbal memory than controls, with significantly worse immediate (p = 0.007) 
and 30 minute delayed recall (p = 0.017) of the list, after adjusting for age and gender (Table 
1). In contrast, patients and controls did not differ in their executive function (Stroop p = 
0.648, Hayling sentence completion p = 0.077), working memory (p = 0.254), visuospatial 
memory (p = 0.232), premorbid IQ (p = 0.092), or on the PASAT (p = 0.140). 63% of 
patients (n = 19) were categorised as cognitively preserved, with only 37% (n = 11) 
categorised as cognitively impaired.  
 
Patients performed significantly worse on all motor and sensory tests, when compared to 
controls, specifically, grip strength (p = 0.001), muscle strength (p = 0.001), 9-HPT (p = 
0.001), TWT (p = 0.001) and VPTs (p = 0.001), after adjusting for age and gender (Table 1).   
 
Structural MRI Measures 
 
Total grey matter DIR lesions in patients ranged from 0 – 32, with a median of 16 lesions. 
The median number of grey matter lesions within each of the spectroscopic VOIs was 0 
(Table 2).  
Patients showed significant whole brain WM atrophy when compared with controls (WM 
fraction: 0.323 vs. 0.340, p < 0.0001), after adjusting for age and gender. There was no 
significant difference in total brain GM fraction (GMF) (p = 0.739), or in the GM or WM 
tissue volumes within the spectroscopic voxels between patients and controls (all p 
values>0.05) (Table 2).  
 
GABA concentration in the hippocampus and sensorimotor cortex was lower in patients 
than controls 
Patients had significantly lower GABA concentration in the hippocampus, reduced by 
0.403mM (95% CIs -0.792, -0.014, p = 0.043), and in the sensorimotor cortex, reduced by 
0.385mM (95% CIs -0.667, -0.104, p = 0.009), when compared with healthy controls, after 
adjusting for age, gender and GMF and WMF within the spectroscopic voxel (Table 3). 
However, there was no significant difference in GABA concentration in the prefrontal cortex 
(p = 0.096) between patients and controls. 
 
Patients also showed a significantly lower tNAA concentration in the sensorimotor cortex by 
2.455mM (p = 0.007) when compared with healthy controls, after adjusting for age, gender 
and GMF and WMF within the spectroscopic voxel. There were no significant differences in 
tNAA levels in the hippocampus (p = 0.512) and prefrontal cortex (p = 0.587) between 
groups after adjusting for the above-mentioned covariates (Table 3).  
 
There were no significant difference in [Glx] in the prefrontal cortex, hippocampus and 
sensorimotor cortex between patients and controls (Table 3).  
 
 
Associations between GABA levels in the sensorimotor cortex and clinical scores 
In patients, worse motor function in the right upper and lower limb was significantly 
associated with lower GABA levels in the sensorimotor cortex, after correcting for age and 
gender. In particular, for each unit decrease in GABA levels, there was a predicted -10.86 
(95% CIs -17.786, - 4.482) decrease in grip strength (kg force) (p < 0.001) and -8.74 (95% 
CIs -13.943, -3.015) decrease in muscle strength of the right upper and lower limb (p < 
0.006), according to the corresponding regression models. Also, per unit decrease in GABA 
levels, there was a predicted borderline significant decrease in the 9-HPT z-score of -1.257 
(95% CIs -2.782, 0.261) (p < 0.10) (Figure 2). These significant associations did not show 
any substantial change (i.e., their regression coefficients did not change) when tNAA and Glx 
levels in the sensorimotor cortex were included into the model. Repeating the regression 
models including age, gender, depression, and premorbid IQ did not change the pattern of 
results. 
 
There were no significant associations between GABA concentration in the sensorimotor 
cortex and the remaining physical disability scores, such as EDSS, TWT, and VPTs, and 
between GABA concentration in either the hippocampal or prefrontal VOI and any of the 
cognitive tests.  
  
 DISCUSSION 
This study provides evidence that (1) GABA levels are reduced in the hippocampus and 
sensorimotor cortex in patients with SPMS and (2) lower GABA concentration in the 
sensorimotor cortex correlates with reduced motor function of the contralateral limbs. We 
will discuss each of these results in turn. 
 
Evidence of GABAergic dysfunction in SPMS 
The observed reduced GABA levels in the hippocampus and sensorimotor cortex in patients 
with SPMS when compared with healthy controls raises the possibility that GABA may be a 
marker of neurodegeneration in the brain. The reduction in GABA levels may reflect a 
combination of reduced GABA receptor levels and decreased density of inhibitory 
interneuron processes in the motor cortex in patients with progressive MS, which have been 
described by a previous histological study (Dutta et al., 2006). A PET imaging study in MS 
using 11C-flumazenil (Freeman et al., 2010), which binds the benzodiazepine site on the 
GABAA receptor, reported that the uptake of 
11C-flumazenil was lower (indicating reduced 
GABAA receptor levels) in the cortex of patients with multiple sclerosis (RRMS and SPMS) 
compared with healthy controls (Freeman et al., 2010), suggesting the loss of dendrites and 
synapses seen at post-mortem analysis (Wegner et al., 2006), which may precede the 
development of measurable brain atrophy. A previous study reported reduced glutamate 
levels in grey matter (cingulate and parietal cortices) in RRMS patients compared to controls, 
suggesting that a reduced availability of the precursor glutamate, may contribute to reduced 
synthesis of GABA. The significant decrease in tNAA concentration in the sensorimotor 
cortex in patients compared to controls confirms that there was significant neuronal loss 
and/or dysfunction in this region, since NAA is a well-established marker of neuroaxonal 
integrity, viability and metabolism (Moffett et al., 2007).   
 
In addition to being a marker of neurodegeneration, decreases in GABA levels may 
contribute to the ongoing neurodegenerative process in progressive MS. Although 
spectroscopic measurements in vivo do not allow us to draw firm conclusions about possible 
changes in the neurotransmitter pool and/or GABAergic pathway, there is some evidence 
from preclinical studies that MRS-derived GABA levels reflect extra-synaptic GABA tone, 
rather than synaptic GABA activity (Mason et al., 2001). Therefore, the observed reduced 
GABA levels may reflect a reduction in inhibitory innervation of cortical neurons, which, in 
turn, upregulates the firing rate of demyelinated axons, resulting in higher energy demands, 
as proposed by Dutta et al., 2006; this may ultimately result in progressive axonal loss and 
neurodegeneration. Additionally, there is evidence that GABA mediates neuroprotection by 
delaying neuronal death (Saji & Reis, 1987). 
 
There was no difference in GABA levels in the prefrontal cortex between patients and 
controls, indicating a regional variation in altered GABA levels. This is likely to reflect 
regional variation in both the reduced synaptic density and neuronal loss, and in the possible 
role of altered GABA concentration, as a mechanism of plasticity and functional 
reorganization, as explained below.  
 
The fact that tNAA was not a significant factor in the models including GABA, and that the 
RC’s for GABA did not materially change when adjusting for tNAA, imply that the 
relationship between lower GABA and poorer clinical performance seemed not to be 
confounded by the levels of tNAA, which could hypothetically be associated with GABA 
levels and with clinical performance.  
 
Association between lower GABA levels and physical disability 
In this study, there were associations between decreased muscle strength and worse 
performance on the 9-HPT, and lower sensorimotor GABA concentration. This suggests that 
greater loss of inhibitory neurons (and their processes) is an important contributor to clinical 
disability. Additionally, reduced GABA levels may represent a mechanism through which 
progressive axonal degeneration leads to progressive neurological disability. Patients with 
SPMS may have a loss of compensatory mechanisms associated with cortical reorganisation 
and adaptation, due to a reduction in synapses and neurons, resulting in the loss or 
deterioration in function.  
 
The observed correlation between worse 9-HPT scores and lower GABA levels in the 
sensorimotor cortex is in contrast to a study by Bhattacharyya et al (2014), as previously 
mentioned. Bhattacharyya et al., found that a worsening of performance on the 9-HPT was 
associated with increased GABA levels in patients with RRMS.  These conflicting findings 
may reflect differences between patient populations (SPMS compared to RRMS). Patients 
with SPMS may have loss of the compensatory mechanisms associated with cortical 
reorganisation (Rocca et al., 2005), as a result of ongoing loss of inhibitory GABA 
neurotransmission, ultimately resulting in progressive neurodegeneration and progressive 
disability. In contrast, in RRMS, reduced GABA levels are associated with improved motor 
performance, as a result of adaptation of cortical grey matter. The inclusion, in the 
Bhattacharyya’s study, of patients currently taking GABAergic medications at the time of 
scanning is a limitation.  
 We found no significant associations between GABA levels in the sensorimotor cortex and 
VPTs, TWT or EDSS. This may be due to the role of regions other than the sensorimotor 
cortex in contributing to the clinical function that is captured by these scores, the small range 
of EDSS (4-6.5) in the patient group, and the impact of changes in regionally specific GABA 
levels on function.  
 
It is surprising that patients’ performance on cognitive tests were not associated with GABA 
levels in relevant brain regions. It is difficult to say why we did not see a relation between 
memory function and GABA levels in the prefrontal cortex and hippocampus grey matter 
regions, but this may be due to a number of reasons. First, the patients recruited into this 
study were relatively early in their progressive disease course (mean duration = 4 years) and 
had no significant GM atrophy. Second, 63% of patients (n = 19) were categorised as 
cognitively preserved, with only 37% (n = 11) categorised as cognitively impaired. Third, a 
sample size calculation with 80% power, at 5% significance, requires an N of 85 to detect a 
significant association between GABA levels and the cognitive tests, which is substantially 
more than the number recruited into this study. Finally, GABA differences may be more 
widespread and so have an effect in relation to memory that is not evident in the single VOI 
studied.  
 
Limitations and future directions 
One limitation of this study is the shape of the spectroscopic VOIs and the linear relationship 
between the VOI volume and spectroscopic SNR. As the regions of interest were small it was 
necessary to have VOIs that encompassed the GM of interest, rather than being completely 
contained within the specific region, in order to achieve reliable measurements of metabolite 
concentrations in acceptable acquisition times. Whilst every effort was made to limit the 
MRS voxel to the GM, the size and shape of the VOIs meant this included some WM from 
surrounding tissue. The correction for WMF and GMF within the spectroscopic voxel in the 
statistical models will have reduced the possibility that differences in these measures between 
groups were responsible for differences in GABA. One study (Bhattacharyya et al., 2011) 
measured GABA in the sensorimotor cortex with similar GMF (37+/-7%) and WMF (52+/-
12%) as to those reported in Table 2. They found that the concentrations of GABA within the 
grey matter and white matter were up to nine times greater in GM compared to WM (2.87+/-
0.61mM versus 0.33+/-0.11mM) (Bhattacharyya et al., 2011), which suggests that the 
majority of the GABA concentration quantified with MRS derives from the GM. 
 
From a technical point of view, the spectral editing cannot separate the GABA signal from 
the macromolecule (MM) component, which may be clinically relevant (Cudalbu et al., 
2012). A number of approaches have been proposed to separate GABA from co-edited MM 
signals, including metabolite nulling (Behar et al., 1994), and symmetric editing-based 
suppression of MM (Henry et al., 2001). Each of these methods have significant detrimental 
effects on the quality of the data as well as the acquisition time (Mullins et al., 2014), and 
MM contamination is frequently accepted as a limitation of this most commonly applied 
approach (Mullins et al., 2014). It has also been reported in the literature, that occipital cortex 
GABA concentration is modulated during the menstrual cycle, with reduced GABA during 
the follicular phase of the cycle (Epperson et al., 2002). We did not correct for menstrual 
cycle in our analysis, but note that this variable would not be relevant as 14 out of 23 female 
patients and 4 of 9 female controls were menopausal. 
 
In the future, it will be useful to follow these patients up over time to see what happens to the 
GABA concentration in these regions, in addition to looking at a cohort of patients with 
RRMS to see how GABA levels differ to patients with progressive MS. Also, it would be 
very useful to combine PET imaging, in particular 11C-flumazenil, with 1H-MRS, to 
investigate the co-localisation of the PET signal changes with the 1H-MRS derived GABA 
changes.  
 
Conclusion 
Using 1H-MRS, we provide the first in vivo evidence that GABA neurotransmission in the 
hippocampus and sensorimotor cortex is reduced in patients with SPMS when compared with 
healthy controls. Lower GABA levels in the sensorimotor cortex of MS patients are 
associated with reduced motor performance. These findings raise the possibility that altered 
GABA neurotransmission may be a marker of neurodegeneration, but it may also suggest that 
GABA is a mechanism of neurodegeneration in progressive MS patients. If we put these 
findings together with the evidence that GABA may mediate neuroprotection, targeting 
GABA may be a productive strategy that should be further explored in MS.  
  
 
Figure Legend 
Figure 1: Placement of MR Spectroscopy (MRS) voxels (left) with their example MRS 
spectra (right) in the prefrontal cortex (A), right hippocampus (B) and the left sensorimotor 
cortex (C) GABA - gamma-aminobutyric acid; tNAA – total N-acetyl-aspartate 
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